Clinical pharmacokinetics and pharmacodynamics of topical non-biological therapies for psoriasis patients

References

• Armstrong AW, Mehta MD, Schupp CW, et al. Psoriasis prevalence in adults in the United States. JAMA Dermatol. 2021;157(8):940–946. doi: 10.1001/jamadermatol.2021.2007
   PubMed Web of Science ®Google Scholar
• Kamiya K, Kishimoto M, Sugai J, et al. Risk factors for the development of psoriasis. Int J Mol Sci. 2019;20(18):4347. doi: 10.3390/ijms20184347
   PubMed Web of Science ®Google Scholar
• Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):20. doi: 10.3390/ijms20061475
   Web of Science ®Google Scholar
• Torsekar R, Gautam MM. Topical therapies in psoriasis. Indian Dermatol Online J. 2017;8(4):235–245. doi: 10.4103/2229-5178.209622
   PubMedGoogle Scholar
• Ahmed SS, Manchanda Y, De A, et al. Topical therapy in psoriasis. Indian J Dermatol. 2023;68(4):437–445. doi: 10.4103/ijd.ijd_422_23
   PubMed Web of Science ®Google Scholar
• Uva L, Miguel D, Pinheiro C, et al. Mechanisms of action of topical corticosteroids in psoriasis. Int J Endocrinol. 2012;2012:561018. doi: 10.1155/2012/561018
   PubMed Web of Science ®Google Scholar
• Guo J, Zhang H, Lin W, et al. Signaling pathways and targeted therapies for psoriasis. Signal Transduct Target Ther. 2023;8(1):437. doi: 10.1038/s41392-023-01655-6
   PubMed Web of Science ®Google Scholar
• Gutfreund K, Bienias W, Szewczyk A, et al. Topical calcineurin inhibitors in dermatology. Part I: properties, method and effectiveness of drug use. Postepy Dermatol Alergol. 2013;30:165–169. doi: 10.5114/pdia.2013.35619
   PubMed Web of Science ®Google Scholar
• Memon N. Corticosteroids: drug class, uses, side effects, drug names [Internet]. RxList; 2022. Available from: http://www.rxlist.com/corticosteroids/drug-class.htm
   Google Scholar
• Kragballe K. Topical corticosteroids: mechanisms of action. Acta Derm Venereol Suppl (Stockh). 1989;151:7–10; discussion 47–52. discussion 47-52.
   PubMedGoogle Scholar
• Gabros S, Nessel TA, Zito PM Topical Corticosteroids. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2024 Feb 1]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK532940/
   Google Scholar
• Dhar S, Seth J, Parikh D. Systemic side-effects of topical corticosteroids. Indian J Dermatol. 2014;59(5):460–464. doi: 10.4103/0019-5154.139874
   PubMed Web of Science ®Google Scholar
• Stacey SK, McEleney M. Topical corticosteroids: choice and application. Am Fam Physician. 2021;103(6):337–343.
   PubMed Web of Science ®Google Scholar
• Sitter B. Urinary detection of corticosteroid in topical treatment of skin disease by 19F MRS. Magn Reson Mater Phy. 2019;32(1):157–162. doi: 10.1007/s10334-018-00734-y
   Web of Science ®Google Scholar
• Andreassi L, Giannetti A, Milani M, et al. Efficacy of betamethasone valerate mousse in comparison with standard therapies on scalp psoriasis: an open, multicentre, randomized, controlled, cross-over study on 241 patients. Br J Dermatol. 2003;148(1):134–138. doi: 10.1046/j.1365-2133.2003.04950.x
   PubMed Web of Science ®Google Scholar
• Smit P, Neumann HAM, Thio HB. The skin-blanching assay. J Eur Acad Dermatol Venereol JEADV. 2012;26(10):1197–1202. doi: 10.1111/j.1468-3083.2012.04449.x
   PubMed Web of Science ®Google Scholar
• Nair AB, Kumar S, Dalal P, et al. Novel dermal delivery cargos of clobetasol propionate: an update. Pharmaceutics. 2022;14(2):383. doi: 10.3390/pharmaceutics14020383
   PubMed Web of Science ®Google Scholar
• Development and characterisation of clobetasol propionate loaded Squarticles as a lipid nanocarrier for treatment of plaque psoriasis - PubMed [Internet]. [cited 2024 Mar 12]. Available from: https://pubmed.ncbi.nlm.nih.gov/32293928/
   Google Scholar
• Ference JD, Last AR. Choosing topical corticosteroids. Am Fam Physician. 2009;79(2):135–140.
   PubMed Web of Science ®Google Scholar
• Ah Y-M, Hwang S, Jun K, et al. Real-world safety evaluation of topical corticosteroid use: a community pharmacy-based, prospective, observational study. Basic Clin Pharmacol Toxicol. 2019;125(4):405–413. doi: 10.1111/bcpt.13238
   PubMed Web of Science ®Google Scholar
• Coondoo A, Phiske M, Verma S, et al. Side-effects of topical steroids: a long overdue revisit. Indian Dermatol Online J. 2014;5(4):416–425. doi: 10.4103/2229-5178.142483
   PubMedGoogle Scholar
• Brookes T-R, Barlow R, Mohandas P, et al. Topical steroid withdrawal: an emerging clinical problem. Clin Exp Dermatol. 2023;48(9):1007–1011. doi: 10.1093/ced/llad161
   PubMed Web of Science ®Google Scholar
• Malecic N, Young H. Tacrolimus for the management of psoriasis: clinical utility and place in therapy. Psoriasis Auckl. 2016;6:153–163. doi: 10.2147/PTT.S101233
   PubMedGoogle Scholar
• Gisondi P, Ellis CN, Girolomoni G. Pimecrolimus in dermatology: atopic dermatitis and beyond. Int J Clin Pr. 2005;59(8):969–974. doi: 10.1111/j.1368-5031.2005.00587.x
   PubMed Web of Science ®Google Scholar
• Novartis. Elidel (pimecrolimus) Cream 1% [Internet]. U.S. Food and Drug Administration; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21302s005lbl.pdf.
   Google Scholar
• Jacobi A, Braeutigam M, Mahler V, et al. Pimecrolimus 1% cream in the treatment of facial psoriasis: a 16-week open-label study. Dermatology. 2008;216(2):133–136. doi: 10.1159/000111510
   PubMed Web of Science ®Google Scholar
• Carroll CL, Clarke J, Camacho F, et al. Topical tacrolimus ointment combined with 6% salicylic acid gel for plaque psoriasis treatment. Arch dermatol. 2005;141(1):43–46. doi: 10.1001/archderm.141.1.43
   PubMedGoogle Scholar
• Vissers WH, van Vlijmen I, van Erp PE, et al. Topical treatment of mild to moderate plaque psoriasis with 0·3% tacrolimus gel and 0·5% tacrolimus cream: the effect on SUM score, epidermal proliferation, keratinization, T-cell subsets and HLA-DR expression. Br J Dermatol. 2008;158(4):705–712. doi: 10.1111/j.1365-2133.2008.08442.x
   PubMed Web of Science ®Google Scholar
• Tirado-Sánchez A, Ponce-Olivera RM. Preliminary study of the efficacy and tolerability of combination therapy with calcipotriene ointment 0.005% and tacrolimus ointment 0.1% in the treatment of stable plaque psoriasis. Cutis. 2012;90(3):140–144.
   PubMed Web of Science ®Google Scholar
• Lapteva M, Mondon K, Möller M, et al. Polymeric micelle nanocarriers for the cutaneous delivery of tacrolimus: a targeted approach for the treatment of psoriasis. Mol Pharm. 2014;11(9):2989–3001. doi: 10.1021/mp400639e
   PubMed Web of Science ®Google Scholar
• PROTOPIC®(tacrolimus) [Internet]. U.S. Food And Drug Administration; 2011 [cited 2024 Jan 31]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/050777s018lbl.pdf
   Google Scholar
• Goodman JJ, Marbury T, Clevinger S Tacrolimus prarmacokinetics in adult and psoriasis patients after topical administration of gel 0.03%, 0.1%, and 0.3%. MOSBY-ELSEVIER 360 PARK AVENUE SOUTH, (NY), NY 10010-1710 USA; 2005. p. P196–P196
   Google Scholar
• Bissonnette R, Nigen S, Bolduc C. Efficacy and tolerability of topical tacrolimus ointment for the treatment of male genital psoriasis. J Cutan Med Surg. 2008;12(5):230–234. doi: 10.2310/7750.2008.07055
   PubMed Web of Science ®Google Scholar
• Gribetz C, Ling M, Lebwohl M, et al. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J Am Acad Dermatol. 2004;51(5):731–738. doi: 10.1016/j.jaad.2004.06.010
   PubMed Web of Science ®Google Scholar
• Martín Ezquerra G, Sánchez Regaña M, Herrera Acosta E, et al. Topical tacrolimus for the treatment of psoriasis on the face, genitalia, intertriginous areas and corporal plaques. J Drugs Dermatol JDD. 2006;5(4):334–336.
   PubMedGoogle Scholar
• Ortonne J-P, van de Kerkhof PCM, Prinz JC, et al. 0.3% tacrolimus gel and 0.5% tacrolimus cream show efficacy in mild to moderate plaque psoriasis: results of a randomized, open-label, observer-blinded study. Acta Derm Venereol. 2006;86(1):29–33. doi: 10.1080/00015550510039817
   PubMed Web of Science ®Google Scholar
• Zonneveld IM, Rubins A, Jablonska S, et al. Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study. Arch dermatol. 1998;134(9):1101–1102. doi: 10.1001/archderm.134.9.1101
   PubMed Web of Science ®Google Scholar
• Kreuter A, Sommer A, Hyun J, et al. 1% pimecrolimus, 0.005% calcipotriol, and 0.1% betamethasone in the treatment of intertriginous psoriasis: a double-blind, randomized controlled study. Arch dermatol. 2006;142(9):1138–1143. doi: 10.1001/archderm.142.9.1138
   PubMedGoogle Scholar
• Chandraratna RA. Tazarotene–first of a new generation of receptor-selective retinoids. Br J Dermatol. 1996;135(Suppl 49):18–25. doi: 10.1111/j.1365-2133.1996.tb15662.x
   PubMedGoogle Scholar
• Duvic M, Nagpal S, Asano AT, et al. Molecular mechanisms of tazarotene action in psoriasis. J Am Acad Dermatol. 1997;37(2):S18–24. doi: 10.1016/S0190-9622(97)80396-9
   PubMed Web of Science ®Google Scholar
• TAZORAC® Cream [Internet]. U.S. Food and Drug Administration; 2013. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021184s007lbl.pdf
   Google Scholar
• Dando TM, Wellington K. Topical tazarotene: a review of its use in the treatment of plaque psoriasis. Am J Clin Dermatol. 2005;6(4):255–272. doi: 10.2165/00128071-200506040-00006
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Ast E, Callen JP, et al. Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis. J Am Acad Dermatol. 1998;38(5):705–711. doi: 10.1016/S0190-9622(98)70594-8
   PubMed Web of Science ®Google Scholar
• 20600 Tazorac 0.05% and 0.1% clinical pharmacology biopharmaceutics Review(s) [Internet]. U.S. Food and Drug Administration; 1966 [cited 2024 Jan 31]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/20600_TAZORAC%200.05%25%20AND%200.1%25_BIOPHARMR_P1.PDF
   Google Scholar
• Menter A. Pharmacokinetics and safety of tazarotene. J Am Acad Dermatol. 2000;43(2):S31–5. doi: 10.1067/mjd.2000.108321
   PubMed Web of Science ®Google Scholar
• Weinstein GD, Koo JY, Krueger GG, et al. Tazarotene cream in the treatment of psoriasis: two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. J Am Acad Dermatol. 2003;48(5):760–767. doi: 10.1067/mjd.2003.103
   PubMed Web of Science ®Google Scholar
• Krueger GG, Drake LA, Elias PM, et al. The safety and efficacy of tazarotene gel, a topical acetylenic retinoid, in the treatment of psoriasis. Arch dermatol. 1998;134(1):57–60. doi: 10.1001/archderm.134.1.57
   PubMedGoogle Scholar
• Stein Gold L, Bagel J, Lebwohl M, et al. Halobetasol and Tazarotene: further defining the role of a unique fixed combination topical lotion in moderate-to-severe plaque psoriasis. J Drugs Dermatol. 2018;17(12):1290–1296.
   PubMed Web of Science ®Google Scholar
• Tanghetti EA. An observation study evaluating the treatment of plaque psoriasis with tazarotene gels, alone and with an emollient and/or corticosteroid. Cutis. 2000;66:4–11.
   PubMedGoogle Scholar
• Green L, Sadoff W. A clinical evaluation of tazarotene 0.1% gel, with and without a high- or mid-high-potency corticosteroid, in patients with stable plaque psoriasis. J Cutan Med Surg. 2002;6(2):95–102. doi: 10.1177/120347540200600201
   PubMed Web of Science ®Google Scholar
• Erol İ, Üstündağ Okur N, Orak D, et al. Tazarotene-loaded in situ gels for potential management of psoriasis: biocompatibility, anti-inflammatory and analgesic effect. Pharm Dev Technol. 2020;25(8):909–918. doi: 10.1080/10837450.2020.1765180
   PubMed Web of Science ®Google Scholar
• Han G, Wu JJ, Del Rosso JQ. Use of Topical Tazarotene for the treatment of acne vulgaris in pregnancy: a literature review. J Clin Aesthetic Dermatol. 2020;13:E59–E65.
   PubMedGoogle Scholar
• Jett JE, McLaughlin M, Lee MS, et al. Tapinarof cream 1% for extensive plaque psoriasis: a maximal use trial on safety, tolerability, and pharmacokinetics. Am J Clin Dermatol. 2022;23:83–91.
   PubMed Web of Science ®Google Scholar
• Lebwohl MG, Stein Gold L, Strober B, et al. Phase 3 trials of tapinarof cream for plaque psoriasis. N Engl J Med. 2021;385(24):2219–2229. doi: 10.1056/NEJMoa2103629
   PubMed Web of Science ®Google Scholar
• Robbins K, Bissonnette R, Maeda-Chubachi T, et al. Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis. J Am Acad Dermatol. 2019;80(3):714–721. doi: 10.1016/j.jaad.2018.10.037
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Vasist LS, Bullman JN, et al. Systemic pharmacokinetics, safety, and preliminary efficacy of topical AhR agonist tapinarof: results of a phase 1 study. Clin Pharmacol Drug Dev. 2018;7(5):524–531. doi: 10.1002/cpdd.439
   PubMed Web of Science ®Google Scholar
• VTAMA® (tapinarof) cream, for topical use [Internet]. U.S. Food and Drug Administration; 2022 [cited 2024 Jan 31]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215272s000lbl.pdf.
   Google Scholar
• Smith SH, Jayawickreme C, Rickard DJ, et al. Tapinarof is a natural AhR agonist that resolves skin inflammation in mice and humans. J Invest Dermatol. 2017;137(10):2110–2119. doi: 10.1016/j.jid.2017.05.004
   PubMed Web of Science ®Google Scholar
• Menter A, Cordoro KM, Davis DMR, et al. Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020;82(1):161–201. doi: 10.1016/j.jaad.2019.08.049
   PubMed Web of Science ®Google Scholar
• Abdallah MA, El-Khateeb EA, Abdel-Rahman SH. The influence of psoriatic plaques pretreatment with crude coal tar vs. petrolatum on the efficacy of narrow-band ultraviolet B: a half-vs.-half intra-individual double-blinded comparative study. Photodermatol Photoimmunol Photomed. 2011;27(5):226–230. doi: 10.1111/j.1600-0781.2011.00602.x
   PubMed Web of Science ®Google Scholar
• Final safety assessment of coal tar as used in cosmetics. Int J Toxicol. 2008;Suppl 27(2_suppl):1–24. doi: 10.1080/10915810802244405
   Google Scholar
• Zeichner JA. Use of topical coal tar foam for the treatment of psoriasis in difficult-to-treat areas. J Clin Aesthet Dermatol. 2010;3(9):37–40.
   PubMedGoogle Scholar
• Menter MA, Whiting DA, McWilliams J. Resistant childhood psoriasis: an analysis of patients seen in a day-care center. Pediatr Dermatol. 1984;2(1):8–12. doi: 10.1111/j.1525-1470.1984.tb00434.x
   PubMedGoogle Scholar
• Belsito DV, Kechijian P. The role of tar in Goeckerman therapy. Arch dermatol. 1982;118(5):319–321. doi: 10.1001/archderm.1982.01650170033018
   PubMedGoogle Scholar
• Bagel J. LCD plus NB-UVB reduces time to improvement of psoriasis vs. NB-UVB alone. J Drugs Dermatol. 2009;8:351–357.
   PubMed Web of Science ®Google Scholar
• Storer JS, DeLeon I, Millikan LE, et al. Human absorption of crude coal tar products. Arch dermatol. 1984;120(7):874–877. doi: 10.1001/archderm.1984.01650430060011
   PubMedGoogle Scholar
• Veenhuis RT, van Horssen J, Bos RP, et al. Highly increased urinary 1-hydroxypyrene excretion rate in patients with atopic dermatitis treated with topical coal tar. Arch Dermatol Res. 2002;294(4):168–171. doi: 10.1007/s00403-002-0311-5
   PubMed Web of Science ®Google Scholar
• van Schooten FJ, Moonen EJ, Rhijnsburger E, et al. Dermal uptake of polycyclic aromatic hydrocarbons after hairwash with coal-tar shampoo. Lancet. 1994;344(8935):1505–1506. doi: 10.1016/S0140-6736(94)90323-9
   PubMed Web of Science ®Google Scholar
• Roelofzen JH, van der Valk PG, Godschalk R, et al. DNA adducts in skin biopsies and 1-hydroxypyrene in urine of psoriasis patients and healthy volunteers following treatment with coal tar. Toxicol Lett. 2012;213(1):39–44. doi: 10.1016/j.toxlet.2011.06.030
   PubMed Web of Science ®Google Scholar
• Roelofzen JH, Aben KK, Oldenhof UT, et al. No increased risk of cancer after coal tar treatment in patients with psoriasis or eczema. J Invest Dermatol. 2010;130(4):953–961. doi: 10.1038/jid.2009.389
   PubMed Web of Science ®Google Scholar
• Kumar U, Kaur I, Dogra S, et al. Topical tazarotene vs. coal tar in stable plaque psoriasis. Clin Exp Dermatol. 2010;35(5):482–486. doi: 10.1111/j.1365-2230.2009.03610.x
   PubMed Web of Science ®Google Scholar
• Thawornchaisit P, Harncharoen K. A comparative study of tar and betamethasone valerate in chronic plaque psoriasis: a study in Thailand. J Med Assoc Thai. 2007;90(10):1997–2002.
   PubMedGoogle Scholar
• Tham SN, Lun KC, Cheong WK. A comparative study of calcipotriol ointment and tar in chronic plaque psoriasis. Br J Dermatol. 1994;131(5):673–677. doi: 10.1111/j.1365-2133.1994.tb04981.x
   PubMed Web of Science ®Google Scholar
• Singh P, Gupta S, Abidi A, et al. Comparative evaluation of topical calcipotriol versus coal tar and salicylic acid ointment in chronic plaque psoriasis. J Drugs Dermatol. 2013;12(8):868–873.
   PubMed Web of Science ®Google Scholar
• Brouda I, Edison B, Van Cott A, et al. Tolerability and cosmetic acceptability of liquor carbonis distillate (coal tar) solution 15% as topical therapy for plaque psoriasis. Cutis. 2010;85(4):214–220.
   PubMed Web of Science ®Google Scholar
• Alora-Palli MB, Perkins AC, Van Cott A, et al. Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream. Am J Clin Dermatol. 2010;11:275–283. doi: 10.2165/11530380-000000000-00000
   PubMed Web of Science ®Google Scholar
• Goodfield M, Kownacki S, Berth-Jones J. Double-blind, randomised, multicentre, parallel group study comparing a 1% coal tar preparation (exorex) with a 5% coal tar preparation (alphosyl) in chronic plaque psoriasis. J Dermatol Treat. 2004;15(1):14–22. doi: 10.1080/09546630310017843
   PubMedGoogle Scholar
• Dyring-Andersen B, Bonefeld CM, Bzorek M, et al. The vitamin D analogue calcipotriol reduces the frequency of CD8+ IL-17+ T cells in psoriasis lesions. Scand J Immunol. 2015;82(1):84–91. doi: 10.1111/sji.12304
   PubMed Web of Science ®Google Scholar
• Franssen MEJ, de Jongh GJ, van Erp PEJ, et al. A left/right comparison of twice-daily calcipotriol ointment and calcitriol ointment in patients with psoriasis: the effect on keratinocyte subpopulations. Acta Derm Venereol. 2004;84(3):195–200. doi: 10.1080/00015550410025930
   PubMed Web of Science ®Google Scholar
• Lung BE, Mowery ML, Komatsu DEE. Calcitriol. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2024 Mar 4]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK526025/
   Google Scholar
• Dovonex Product Monograph. Leo Pharma. 2021. [accessed 2024 Jan 31]. https://pdf.hres.ca/dpd_pm/00064010.PDF
   Google Scholar
• Huovinen J, Haj Hussain M, Niemelä M, et al. Pharmacokinetics of intra-articular vitamin D analogue calcipotriol in sheep and metabolism in human synovial and mesenchymal stromal cells. J Steroid Biochem Mol Biol. 2019;188:172–184. doi: 10.1016/j.jsbmb.2018.12.006
   PubMed Web of Science ®Google Scholar
• Körver JEM, Vissers WHPM, Van Rens DWA, et al. A double‐blind, randomized quantitative comparison of calcitriol ointment and calcipotriol ointment on epidermal cell populations, proliferation and differentiation. Br J Dermatol. 2007;156(1):130–137. doi: 10.1111/j.1365-2133.2006.07561.x
   PubMed Web of Science ®Google Scholar
• Cattoretti G, Becker MH, Key G, et al. Monoclonal antibodies against recombinant parts of the ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol. 1992;168(4):357–363. doi: 10.1002/path.1711680404
   PubMed Web of Science ®Google Scholar
• Weiss RA, Eichner R, Sun TT. Monoclonal antibody analysis of keratin expression in epidermal diseases: a 48- and 56-kdalton keratin as molecular markers for hyperproliferative keratinocytes. J Cell Bio. 1984;98(4):1397–1406. doi: 10.1083/jcb.98.4.1397
   PubMed Web of Science ®Google Scholar
• Kragballe K, Gjertsen BT, De Hoop D, et al. Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet Lond Engl. 1991;337:193–196. doi: 10.1016/0140-6736(91)92157-W
   PubMed Web of Science ®Google Scholar
• Zhu X, Wang B, Zhao G, et al. An investigator-masked comparison of the efficacy and safety of twice daily applications of calcitriol 3 µg/g ointment vs. calcipotriol 50 µg/g ointment in subjects with mild to moderate chronic plaque-type psoriasis. J Eur Acad Dermatol Venereol. 2007;21(4):466–472. doi: 10.1111/j.1468-3083.2006.01913.x
   PubMed Web of Science ®Google Scholar
• Ortonne JP, Humbert P, Nicolas JF, et al. Intra‐individual comparison of the cutaneous safety and efficacy of calcitriol 3 µg g−1 ointment and calcipotriol 50 µg g−1 ointment on chronic plaque psoriasis localized in facial, hairline, retroauricular or flexural areas. Br J Dermatol. 2003;148(2):326–333. doi: 10.1046/j.1365-2133.2003.05228.x
   PubMed Web of Science ®Google Scholar
• Simionescu AA, Danciu BM, Stanescu AMA. State-of-the-art review of pregnancy-related psoriasis. Med Kaunas Lith. 2021;57(8):804. doi: 10.3390/medicina57080804
   PubMed Web of Science ®Google Scholar
• Dovonex (calcipotriene) Cream, 0.005% - Package Insert. 2015. [accessed 2024 Jan 31]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020273s013,020554s012lbl.pdf
   Google Scholar
• Calcitriol topical (Vectical) Use During Pregnancy [Internet]. [cited 2024 Mar 9]. Available from: https://www.drugs.com/pregnancy/calcitriol-topical.html
   Google Scholar
• van de Kerkhof PCM, Green C, Hamberg KJ, et al. Safety and efficacy of combined high-dose treatment with calcipotriol ointment and solution in patients with psoriasis. Dermatology. 2002;204(3):214–221. doi: 10.1159/000057884
   PubMed Web of Science ®Google Scholar
• Lung BE, Mowery ML, Calcitriol KD. StatPearls [internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2024 Mar 12]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK526025/
   Google Scholar
• Schwarb FP, Gabard B, Rufli T, et al. Percutaneous absorption of salicylic acid in man after topical administration of three different formulations. Dermatology. 1999;198(1):44–51. doi: 10.1159/000018063
   PubMed Web of Science ®Google Scholar
• Taylor JR, Halprin KM. Percutaneous absorption of salicylic acid. Arch dermatol. 1975;111(6):740–743. doi: 10.1001/archderm.1975.01630180068008
   PubMed Web of Science ®Google Scholar
• Birmingham BK, Greene DS, Rhodes CT. Systemic absorption of topical salicylic acid. Int J Dermatol. 1979;18(3):228–231. doi: 10.1111/ijd.1979.18.3.228
   PubMed Web of Science ®Google Scholar
• Stolar ME, Rossi GV, Barr M. The effect of various ointment bases on the percutaneous absorption of salicylates II**Received July 16, 1959, from the Philadelphia College of Pharmacy and Science, Philadelphia 4, Pa. J Am Pharm Assoc Am Pharm Assoc. 1960;49(3):148–152. doi: 10.1002/jps.3030490307
   PubMedGoogle Scholar
• Gip L, Hamfelt A. Percutaneous absorption of betamethasone-17, 21-dipropionate and salicylic acid during the treatment of psoriasis and eczema. J Int Med Res. 1976;4(2):106–110. doi: 10.1177/030006057600400204
   PubMed Web of Science ®Google Scholar
• Cosmetic Ingredient Review Expert Panel. Safety assessment of salicylic acid, butyloctyl salicylate, calcium salicylate, C12-15 alkyl salicylate, capryloyl salicylic acid, hexyldodecyl salicylate, isocetyl salicylate, isodecyl salicylate, magnesium salicylate, MEA-Salicylate, ethylhexyl salicylate, potassium salicylate, methyl salicylate, myristyl salicylate, sodium salicylate, TEA-Salicylate, and tridecyl salicylate. Int J Toxicol. 2003;22(Suppl 3):1–108.
   Google Scholar
• Draelos ZD. The efficacy and tolerability of turmeric and salicylic acid in psoriasis treatment. Psoriasis Auckl. 2022;12:63–71. doi: 10.2147/PTT.S360448
   PubMed Web of Science ®Google Scholar
• Kircik L. Salicylic acid 6% in an ammonium lactate emollient foam vehicle in the treatment of mild-to-moderate scalp psoriasis. J Drugs Dermatol. 2011;10(3):270–273.
   PubMed Web of Science ®Google Scholar
• Seité S, Paries J, Reygagne P, et al. A lipohydroxyacid-containing shampoo improves scalp condition and quality of life in patients with seborrheic dermatitis and light-to-moderate scalp psoriasis. J Cosmet Dermatol. 2009;8(2):108–113. doi: 10.1111/j.1473-2165.2009.00431.x
   PubMed Web of Science ®Google Scholar
• Ilknur T, Akarsu S, Aktan S, et al. Comparison of the effects of pulsed dye laser, pulsed dye laser + salicylic acid, and clobetasole propionate + salicylic acid on psoriatic plaques. Dermatol Surg. 2006;32(1):49–55. doi: 10.1097/00042728-200601000-00008
   PubMed Web of Science ®Google Scholar
• Fetil E, Ozka S, Soyal MC, et al. Effects of topical petrolatum and salicylic acid on the erythemogenicity of UVB. Eur J Dermatol. 2002;12(2):154–156.
   PubMed Web of Science ®Google Scholar
• Goruntla N, Arakala G, Nelluri G, et al. Comparison of efficacy, safety, and cost-effectiveness of topical salicylic acid 6% versus clobetasol propionate 0.05% in the treatment of limited chronic plaque psoriasis [internet]. J Health Res Rev. 2018;5(2):86–92. Available from: https://www.jhrr.org/article.asp?issn=2394-2010;year=2018;volume=5;issue=2;spage=86;epage=92;aulast=Goruntla
   Google Scholar
• Khandpur S, Sharma VK. Comparison of clobetasol propionate cream plus coal tar vs. topical psoralen and solar ultraviolet a therapy in palmoplantar psoriasis. Clin Exp Dermatol. 2011;36(6):613–616. doi: 10.1111/j.1365-2230.2011.04061.x
   PubMed Web of Science ®Google Scholar
• Medansky RS, Cuffie CA, Tanner DJ. Mometasone furoate 0.1%—salicylic acid 5% ointment twice daily versus fluocinonide 0.05% ointment twice daily in the management of patients with psoriasis. Clin Ther. 1997;19(4):701–709. doi: 10.1016/S0149-2918(97)80094-X
   PubMed Web of Science ®Google Scholar
• Madan RK, Levitt J. A review of toxicity from topical salicylic acid preparations. J Am Acad Dermatol. 2014;70(4):788–792. doi: 10.1016/j.jaad.2013.12.005
   PubMed Web of Science ®Google Scholar
• Chin RL, Olson KR, Dempsey D. Salicylate toxicity from ingestion and continued dermal absorption. Calif J Emerg Med. 2007;8:23–25.
   PubMedGoogle Scholar
• Cawley EP, Wheeler CE. Salicylic acid poisoning in dermatological therapy. J Am Med Assoc. 1953;151(5):372–374.
   PubMed Web of Science ®Google Scholar
• Nicolas SE, Bear MD, Kanaan AO, et al. Roflumilast 0.3% cream: a phosphodiesterase 4 inhibitor for the treatment of chronic plaque psoriasis. Am J Ther. 2023;30(6):e535–e542. doi: 10.1097/MJT.0000000000001678
   PubMed Web of Science ®Google Scholar
• ZORYVETM (roflumilast) cream, for topical use [Internet]. U.S. Food and Drug Administration; 2022 [cited 2024 Jan 31]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215985s000lbl.pdf
   Google Scholar
• Thurston AW, Osborne DW, Snyder S, et al. Pharmacokinetics of Roflumilast Cream in chronic plaque psoriasis: data from phase I to phase III studies. Am J Clin Dermatol. 2023;24(2):315–324. doi: 10.1007/s40257-022-00741-9
   PubMed Web of Science ®Google Scholar
• Roflumilast. Am J Health Syst Pharm. 2022;79(23):2086–2087. doi: 10.1093/ajhp/zxac249
   PubMedGoogle Scholar
• O’Toole A, Gooderham M. Topical Roflumilast for Plaque Psoriasis. Skin Ther Lett. 2023;28:1–4.
   PubMedGoogle Scholar
• Snape SD, Wigger-Alberti W, Goehring UM. A phase I randomized trial to assess the effect on skin infiltrate thickness and tolerability of topical phosphodiesterase inhibitors in the treatment of psoriasis vulgaris using a modified psoriasis plaque test. Br J Dermatol. 2016;175:479–486.
   PubMed Web of Science ®Google Scholar
• Papp KA, Gooderham M, Droege M, et al. Roflumilast cream improves signs and symptoms of plaque psoriasis: results from a phase 1/2a randomized, controlled study. J Drugs Dermatol. 2020;19(8):734–740. doi: 10.36849/JDD.2020.5370
   PubMed Web of Science ®Google Scholar
• Lebwohl MG, Papp KA, Stein Gold L, et al. Trial of roflumilast cream for chronic plaque psoriasis. N Engl J Med. 2020;383(3):229–239. doi: 10.1056/NEJMoa2000073
   PubMed Web of Science ®Google Scholar
• Lee H-J, Kim M. Challenges and future trends in the treatment of psoriasis. Int J Mol Sci. 2023;24(17):13313. doi: 10.3390/ijms241713313
   PubMed Web of Science ®Google Scholar
• Wollina U, Tirant M, Vojvodic A, et al. Treatment of psoriasis: novel approaches to topical delivery. Open Access Maced J Med Sci. 2019;7(18):3018–3025. doi: 10.3889/oamjms.2019.414
   PubMedGoogle Scholar
• Ahmad MZ, Mohammed AA, Algahtani MS, et al. Nanoscale topical pharmacotherapy in management of psoriasis: Contemporary Research and scope. J Funct Biomater. 2022;14(1):19. doi: 10.3390/jfb14010019
   PubMed Web of Science ®Google Scholar
• Alinia H, Moradi Tuchayi S, Smith JA, et al. Long-term adherence to topical psoriasis treatment can be abysmal: a 1-year randomized intervention study using objective electronic adherence monitoring. Br J Dermatol. 2017;176(3):759–764. doi: 10.1111/bjd.15085
   PubMed Web of Science ®Google Scholar
• Carroll CL, Feldman SR, Camacho FT, et al. Better medication adherence results in greater improvement in severity of psoriasis. Br J Dermatol. 2004;151(4):895–897. doi: 10.1111/j.1365-2133.2004.06174.x
   PubMed Web of Science ®Google Scholar
• Uhlenhake EE, Kurkowski D, Feldman SR. Conversations on psoriasis–what patients want and what physicians can provide: a qualitative look at patient and physician expectations. J Dermatol Treat. 2010;21(1):6–12. doi: 10.3109/09546630903085328
   PubMed Web of Science ®Google Scholar
• Cork MJ, Britton J, Butler L, et al. Comparison of parent knowledge, therapy utilization and severity of atopic eczema before and after explanation and demonstration of topical therapies by a specialist dermatology nurse. Br J Dermatol. 2003;149(3):582–589. doi: 10.1046/j.1365-2133.2003.05595.x
   PubMed Web of Science ®Google Scholar
• Brown KK, Rehmus WE, Kimball AB. Determining the relative importance of patient motivations for nonadherence to topical corticosteroid therapy in psoriasis. J Am Acad Dermatol. 2006;55(4):607–613. doi: 10.1016/j.jaad.2005.12.021
   PubMed Web of Science ®Google Scholar
• Balato N, Megna M, Di Costanzo L, et al. Educational and motivational support service: a pilot study for mobile-phone-based interventions in patients with psoriasis. Br J Dermatol. 2013;168(1):201–205. doi: 10.1111/j.1365-2133.2012.11205.x
   PubMed Web of Science ®Google Scholar
• Feldman SR, Camacho FT, Krejci-Manwaring J, et al. Adherence to topical therapy increases around the time of office visits. J Am Acad Dermatol. 2007;57(1):81–83. doi: 10.1016/j.jaad.2007.04.005
   PubMed Web of Science ®Google Scholar
• Kragballe K, Austad J, Barnes L, et al. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet ® /Daivobet ® /Taclonex ®) in the treatment of psoriasis vulgaris. Br J Dermatol. 2006;154(6):1155–1160. doi: 10.1111/j.1365-2133.2006.07236.x
   PubMed Web of Science ®Google Scholar
• Norsgaard H, Kurdykowski S, Descargues P, et al. Calcipotriol counteracts betamethasone-induced decrease in extracellular matrix components related to skin atrophy. Arch Dermatol Res. 2014;306(8):719–729. doi: 10.1007/s00403-014-1485-3
   PubMed Web of Science ®Google Scholar
• Lebwohl MG, Breneman DL, Goffe BS, et al. Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis. J Am Acad Dermatol. 1998;39(4 Pt 1):590–596. doi: 10.1016/S0190-9622(98)70008-8
   PubMed Web of Science ®Google Scholar
• Bell MA, Whang KA, Thomas J, et al. Racial and ethnic disparities in access to emerging and frontline therapies in common dermatological conditions: a cross-sectional study. J Natl Med Assoc. 2020;112(6):650–653. doi: 10.1016/j.jnma.2020.06.009
   PubMed Web of Science ®Google Scholar
• Balkrishnan R, Bhosle MJ, Fleischer AB, et al. Prior authorization for topical psoriasis treatments: is it cost-beneficial for managed care? J Dermatol Treat. 2010;21(3):178–184. doi: 10.3109/09546630903268247
   PubMed Web of Science ®Google Scholar
• Pimecrolimus: Drug information [Internet]. UptoDate. [cited 2024 Jan 31]. Available from: https://medilib.ir/uptodate/show/10162
   Google Scholar
• TAZORAC® (tazarotene) Gel, 0.05% (tazarotene) Gel, 0.1% [Internet]. U.S. Food and Drug Administration; 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020600s009lbl.pdf.
   Google Scholar
• Coal tar: uses, interactions, mechanism of action | DrugBank online [Internet]. [cited 2024 Jan 31]. Available from: https://go.drugbank.com/drugs/DB11082
   Google Scholar